An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE).

drug protocol number

CZOL446H-MAX-SA-01

drug sponsor

Novartis

drug study

Zoledronic acid

drug trial site

King Fahad University Hospital (Al-Khobar), King Khalid University Hospital (Riyadh)

drug status

Completed

drug phase